Muthiah M N, Michaelides M, Child C S, Mitchell S M
The Western Eye Hospital, Marylebone Road, London NW1 5YE, UK.
Br J Ophthalmol. 2007 Nov;91(11):1452-5. doi: 10.1136/bjo.2007.114884. Epub 2007 May 15.
To determine the incidence, methods of diagnosis, treatment strategies and outcomes for acute retinal necrosis (ARN) in the UK.
A 12-month active case ascertainment study was carried out between March 2001 and March 2002 to record cases of ARN presenting to ophthalmologists via the British Ophthalmological Surveillance Unit (BOSU) reporting system. Questionnaires were sent to the reporting consultants, requesting data on patient characteristics, presentation, clinical findings, investigations and treatment. Diagnosis was made using the American Uveitis Society diagnostic criteria. Further questionnaires were sent at 2 weeks and 6 months to assess outcome and therapies.
74 cases of ARN were reported by 58 consultants between March 2001 and March 2002. Questionnaires were returned for 49 cases (66.2%), of which 18 (36.7%) were excluded. Of the 31 cases included, 22 (71.0%) were male and 9 (29.0%) were female. The age range was 13 to 85 years (mean 54.3 years). 28 cases (90.3%) were unilateral, with 3 patients (9.7%) presenting with bilateral ARN. An aqueous or vitreous biopsy was performed in only 18 patients, with one patient having both. Herpes viral DNA analysis was performed on all 19 biopsies, with identification of the viral DNA in 16; results from 3 biopsies were not documented. Varicella zoster virus (VZV) was the commonest cause identified in 10 patients (56%). Of the 31 subjects, 27 (87.1%) were treated for ARN with systemic antiviral treatment: with intravenous antiviral in 23 cases (85.2%) and oral antiviral in 4 cases (14.8%). 21 of these patients went on to receive oral antiviral maintenance therapy. In addition to antiviral treatment, systemic steroids were given to 16 subjects (51.6%). Surgical intervention for retinal detachment was performed on 5 patients.
During the 12-month study period, 31 cases of ARN met the diagnostic criteria set by the American Uveitis Society. The incidence in the UK based on this study is approximately 1 case per 1.6 to 2.0 million population per year. We have ascertained that the management of ARN throughout the UK is variable, suggesting that national guidelines would be of benefit.
确定英国急性视网膜坏死(ARN)的发病率、诊断方法、治疗策略及预后。
在2001年3月至2002年3月期间开展了一项为期12个月的主动病例确诊研究,以记录通过英国眼科监测单位(BOSU)报告系统向眼科医生报告的ARN病例。向报告的会诊医生发送问卷,索要有关患者特征、临床表现、临床检查结果、检查及治疗的数据。诊断采用美国葡萄膜炎学会的诊断标准。在2周和6个月时再次发送问卷,以评估预后及治疗情况。
2001年3月至2002年3月期间,58位会诊医生报告了74例ARN病例。共收回49例(66.2%)的问卷,其中18例(36.7%)被排除。纳入的31例中,22例(71.0%)为男性,9例(29.0%)为女性。年龄范围为13至85岁(平均54.3岁)。28例(90.3%)为单眼发病,3例(9.7%)为双眼发病。仅18例患者进行了房水或玻璃体活检,其中1例患者两者均做了。对所有19份活检标本进行了疱疹病毒DNA分析,16份检测到病毒DNA;3份活检标本的结果未记录。水痘带状疱疹病毒(VZV)是最常见的病因,10例患者(56%)检测到该病毒。31例患者中,27例(87.1%)接受了ARN的全身抗病毒治疗:23例(85.2%)采用静脉抗病毒治疗,4例(14.8%)采用口服抗病毒治疗。其中21例患者继续接受口服抗病毒维持治疗。除抗病毒治疗外,16例患者(51.6%)接受了全身类固醇治疗。5例患者因视网膜脱离接受了手术干预。
在为期12个月的研究期间,31例ARN病例符合美国葡萄膜炎学会设定的诊断标准。基于本研究,英国的年发病率约为每160万至200万人口中有1例。我们确定,英国各地对ARN的治疗方法不一,这表明制定全国性指南将有所帮助。